Allos Therapeutics Reports Third Quarter 2001 Financial Results
...``Patient accrual for our Phase III randomized study of RSR13 combined with standard whole brain radiation therapy versus standard whole brain radiation therapy alone for the treatment of......The Company is conducting a pivotal Phase III trial for the treatment of metastatic brain tumors with its lead clinical candidate, RSR13.......By increasing tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard radiation therapy...
Oct 18 9:02 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/011018/lath036_1.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines